| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
41,504,000 |
| Market
Cap: |
1.35(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$21.06 - $40.91 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 625 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Collegium Pharmaceutical is a pharmaceutical company. Co.'s portfolio includes: Xtampza ER, Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol. Xtampza ER was approved by the U.S. Food and Drug Administration for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
137,001 |
244,681 |
382,081 |
1,004,450 |
| Total Sell Value |
$4,598,859 |
$7,967,692 |
$11,068,318 |
$25,236,488 |
| Total People Sold |
2 |
4 |
5 |
7 |
| Total Sell Transactions |
3 |
10 |
15 |
42 |
| End Date |
2024-03-01 |
2023-11-29 |
2023-05-31 |
2022-05-31 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Heffernan Michael Thomas |
Director |
– • – |
2018-08-03 |
4 |
D |
$20.15 |
$13,460 |
D/D |
(668) |
388,025 |
|
- |
|
| Brannelly Paul |
Executive Vice President & CFO |
• – – |
2018-07-27 |
4 |
A |
$15.84 |
$8,538 |
D/D |
539 |
123,975 |
|
- |
|
| Dreyer Scott |
EVP & Chief Commercial Officer |
• – – |
2018-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
16,186 |
16,186 |
|
- |
|
| Ciaffoni Joseph |
President and CEO |
• • – |
2018-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
25,140 |
113,341 |
|
- |
|
| Brannelly Paul |
Executive Vice President & CFO |
• – – |
2018-06-21 |
4 |
AS |
$27.50 |
$279,165 |
D/D |
(10,000) |
123,436 |
|
- |
|
| Heffernan Michael Thomas |
Chairman, President and CEO |
• • – |
2018-06-12 |
4 |
S |
$25.26 |
$1,340,220 |
D/D |
(53,057) |
388,693 |
|
- |
|
| Fleming Alison B |
Chief Technology Officer |
• – – |
2018-06-12 |
4 |
AS |
$27.00 |
$110,592 |
D/D |
(4,096) |
53,362 |
|
- |
|
| Heffernan Michael Thomas |
Chairman, President and CEO |
• • – |
2018-06-11 |
4 |
S |
$25.28 |
$2,450,719 |
D/D |
(96,943) |
441,750 |
|
- |
|
| Ciaffoni Joseph |
Chief Operating Officer |
• – – |
2018-06-01 |
4 |
AS |
$22.48 |
$334,098 |
D/D |
(14,862) |
88,201 |
|
- |
|
| Ciaffoni Joseph |
Chief Operating Officer |
• – – |
2018-05-31 |
4 |
D |
$22.62 |
$140,357 |
D/D |
(6,205) |
103,063 |
|
- |
|
| Ciaffoni Joseph |
Chief Operating Officer |
• – – |
2018-05-31 |
4 |
AS |
$22.54 |
$1,465,615 |
D/D |
(64,821) |
109,268 |
|
- |
|
| Ciaffoni Joseph |
Chief Operating Officer |
• – – |
2018-05-31 |
4 |
OE |
$8.22 |
$532,829 |
D/D |
64,821 |
174,089 |
|
- |
|
| Fallon John A. |
Director |
– • – |
2018-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,253 |
4,628 |
|
- |
|
| Melincoff Gwen A |
Director |
– • – |
2018-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,253 |
2,253 |
|
- |
|
| Freund John Gordon |
Director |
– • – |
2018-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,253 |
2,253 |
|
- |
|
| Schroeder Theodore R |
Director |
– • – |
2018-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,253 |
2,253 |
|
- |
|
| Bohlin Garen G |
Director |
– • – |
2018-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,253 |
2,253 |
|
- |
|
| Santini Gino |
Director |
– • – |
2018-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,253 |
25,441 |
|
- |
|
| Hirsch David |
Director |
– • – |
2018-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,253 |
27,193 |
|
- |
|
| Fleming Alison B |
Chief Technical Officer |
• – – |
2018-05-10 |
4 |
AS |
$27.00 |
$37,800 |
D/D |
(1,400) |
154,764 |
|
- |
|
| Heffernan Michael Thomas |
Chairman, President and CEO |
• • – |
2018-05-10 |
4 |
AS |
$26.00 |
$186,100 |
D/D |
(7,100) |
538,693 |
|
- |
|
| Heffernan Michael Thomas |
Chairman, President and CEO |
• • – |
2018-04-19 |
4 |
AS |
$26.00 |
$1,154,401 |
D/D |
(44,400) |
545,793 |
|
- |
|
| Kuhlmann Shirley R. |
EVP and General Counsel |
• – – |
2018-04-04 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
| Fleming Alison B |
Chief Technology Officer |
• – – |
2018-04-02 |
4 |
OE |
$0.28 |
$2,280 |
D/D |
8,142 |
57,458 |
|
- |
|
| Freund John Gordon |
Director |
– • – |
2018-03-19 |
4 |
A |
$0.00 |
$0 |
I/I |
8,791 |
20,506 |
|
- |
|
391 Records found
|
|
Page 12 of 16 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.77 (2.32%) 
